|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 14, 2016 ) Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.
Report Summary:
The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/constipation-pipeline-review-h2-2016
Scope:
- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
- The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Constipation
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001372915/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
AlbireoPharma
Ardelyx, Inc.
Astellas Pharma Inc.
Braintree Laboratories, Inc.
CJ HealthCare Corp.
EA Pharma Co Ltd
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Motus Therapeutics Inc
NGM Biopharmaceuticals, Inc.
RaQualia Pharma Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Torrent Pharmaceuticals Limited
Yuhan Corporation
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001372915/discount
List of Tables
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Constipation - Pipeline by AlbireoPharma, H2 2016 21
Constipation - Pipeline by Ardelyx, Inc., H2 2016 22
Constipation - Pipeline by Astellas Pharma Inc., H2 2016 23
Constipation - Pipeline by Braintree Laboratories, Inc., H2 2016 24
Constipation - Pipeline by CJ HealthCare Corp., H2 2016 25
Constipation - Pipeline by EA Pharma Co Ltd, H2 2016 26
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 27
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 28
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
